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mortality. But in Korea, there were no available data about the effectiveness and safety of lacidipine.
Objectives: The goal of our study was to compare the effect of lacidipine and amlodipine besylate on
sitting systolic blood pressure (SBP) and edema regression time as primary parameters, and sitting
diastolic blood pressure (DBP) and tolerability as a secondary parameter in patients with hypertension.
Method: This was a prospective, randomized, open-label, noninferiority study in which patients received
14 weeks of treatment with either lacidipine or amlodipine besylate. Patients aged 55 to 80 years having
uncomplicated, mild-to-moderate essential hypertension (SBP 140 to o180 mm Hg or DBP Z90 mm Hg)
and receiving no antihypertensive medications during the 2 weeks before randomization were randomly
assigned to receive lacidipine or amlodipine. The incidence of adverse events was also assessed.
Results: In total, 315 patients (154 men, mean age 67.6 years) were included in the intent-to-treat analysis and
randomly assigned to receive lacidipine (n ¼ 162) or amlodipine besylate (n ¼ 153); 286 patients were
included in the per-protocol analysis (n ¼ 150 for lacidipine, n ¼ 136 for amlodipine) (12 in the lacidipine
group and 17 in the amlodipine groupwere excluded from the per-protocol analysis due to consent withdrawal
or protocol violation). There were no differences in demographic proﬁles between the 2 groups. Mean (SD) SBP
changes at 14 weeks were 18.9 (12.7) mm Hg in the lacidipine group and 20.6 (12.4) mm Hg in the
amlodipine group (P 40.05). Because the 1-sided 95% CI for the difference in mean SBP changes between
groups (4.18 to 0.72) was within the pre-speciﬁed lower limit (5 mm Hg), lacidipine was considered
noninferior to amlodipine. There were no differences inmean edema regression time and inmean DBP changes.
These results were consistent in the isolated systolic hypertension subgroup analysis. The overall incidence of
clinical adverse events was comparable between the 2 groups (ie, 7.4% in the lacidipine group and 11.1% in the
amlodipine group [P 40.05]). The most common adverse events were headache and facial ﬂushing (5 out of
162 patients [3.1%] in the lacidipine group and 11 out of 153 patients [7.2%] in the amlodipine group].
Conclusions: Fourteen weeks of lacidipine treatment signiﬁcantly reduced blood pressure in older Korean
patients with mild-to-moderate hypertension. The efﬁcacy of lacidipine was not inferior to that of amlodipine
besylate and tolerability was comparable between the 2 treatment groups. ClinicalTrials.gov identiﬁer:
NCT00460915.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY license.ier Inc.
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Arterial hypertension is a major public health problem in
developed as well as developing countries. It has been shown
that adequate control of blood pressure could reduce cardiovas-
cular morbidity and mortality. Changing patterns of blood
pressure occur with increasing age. In elderly patients, systolicse.
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diastolic blood pressure (DBP) increases until age 55 or 60 years
then tends to decrease later in life. Hypertension in elderly
patients is characterized principally by increased systolic blood
pressure, predominantly isolated systolic hypertension (ISH),
in contrast to the patterns in young adults.1 ISH is considered
a clinically very important cardiovascular risk factor because
an increase in SBP alone, without an increase in DBP, can
increase the incidence of cardiovascular and cerebrovascular
events and all-cause mortality.2,3 However, several studies have
shown that antihypertensive therapy also reduces cardiovascular
morbidity and mortality in patients with ISH, indicating that this
risk factor could be controlled with adequate antihypertensive
treatment. The Systolic Hypertension in the Elderly Program4
study showed that treatment with thiazide reduced cardio-
vascular morbidity and mortality rates signiﬁcantly more than
those treated with placebo. In the Systolic Hypertension in
Europe trial5 and Systolic Hypertension in China trial6 con-
ducted in older patients with isolated SBP, similar results were
observed after treatment with dihydropyridine calcium channel
blockers (CCBs).
To date, many studies have been conducted to evaluate the
effect of various antihypertensive drugs in elderly patients with
hypertension; however, in many of these studies, only limited
subgroup analyses of patients with either systolic or diastolic
hypertension were performed,7 and no sufﬁcient data on the
prevention of hypertension-related complications in elderly
patients were provided.
Lacidipine is a third-generation CCB in the dihydropyridine
group. According to the The Systolic Hypertension in the Elderly:
Lacidipine Long-term Study8 conducted in elderly patients with
isolated systolic hypertension, lacidipine could reduce SBP effec-
tively and safely; there was no signiﬁcant difference in the
cardiovascular morbidity and mortality between the lacidipine
group and the chlorthalidone group. However, there is insufﬁcient
data on the effects of lacidipine on the older Korean population.
The aim of our study was to compare the safety and efﬁcacy of
lacidipine with amlodipine besylate, the most commonly used
calcium antagonist in Korea.Patients and Methods
This was a Phase IV, 14-week, prospective, randomized, open-
label, noninferiority clinical trial conducted at 13 sites in Korea.
Patients were enrolled and randomized from February 2007 to
August 2009, and the randomized patients were followed until
January 2010. The study protocol was approved by both national
and regional review boards. This study was conducted in accord-
ance with the Declaration of Helsinki/Good Clinical Practice
Guideline and its amendments.Inclusion and Exclusion Criteria
This study was conducted in Korean adults aged between 55
and 80 years who had uncomplicated, mild-to-moderate essential
hypertension (sitting SBP [SiSBP] Z140 mm Hg or sitting DBP
[SiDBP] Z90 mm Hg, after a 2-week washout).
Patients were excluded from this study if they had severe
hypertension (SiSBP Z180 mm Hg), secondary hypertension, a
history of myocardial infarction or unstable angina pectoris,
congestive heart failure, anemia (hemoglobin o10.0 g/dL),
renal disease (serum creatinine concentration 41.4 mg/dL),
coagulopathy, peripheral arterial disease, hepatic disease (aspar-
tate aminotransferase [AST] or alanine aminotransferase [ALT]42.5-fold the upper limit of normal), uncontrolled diabetes
(glycosylated hemoglobin [HbA1c] 48.0%), a history of metabolic
acidosis or diabetic ketoacidosis, cancer, known hypersensitivity
to CCBs, alcoholism, or other drug addiction.
Written informed consent was obtained from all eligible
patients before the study.Treatments
Patients had study visits at the beginning and end of the 2-
week washout period and at Week 2, 4, 6, 10, and 14 of drug
treatment. Safety dropout evaluation was performed 2 weeks
after the end of treatment (Week 16 of drug treatment) via
telephone interview or clinic visit. Patients were randomly
assigned, using a method of stratiﬁed block randomization by
site, to receive either lacidipine or amlodipine besylate for
14 weeks.
For the ﬁrst 2 weeks, patients received either lacidipine 2 mg
or amlodipine 2.5 mg in the morning. Patients achieving the
target blood pressure level (SBP o140 mm Hg and DBP o90 mm
Hg) at Week 2 were maintained at the initial dose. Patients who
did not achieve the target blood pressure level were titrated to
lacidipine 4 mg or amlodipine 5 mg. At Week 6 of drug treatment,
patients who failed to reach the target blood pressure level were
titrated to lacidipine 6 mg or amlodipine 10 mg, and those who
still failed to reach the target blood pressure level at Week 10
were given thiazide diuretics (ie, hydrochlorodichlozide 12.5 mg)
in addition. Concomitant use of statins or thiazolidinediones was
permitted during a 14-week treatment period; however, dose
increase or reduction was not allowed. Other medications or
substances that may interact with the study drug were prohibited
during the study period. These include other types of antihyper-
tensive medications, psychotropic agents, oral steroids, daily
nonsteroidal anti-inﬂammatory drugs, estrogen, and antioxidant
vitamin supplements.Assessments
Effectiveness
At the initial screening visit, patients underwent a complete
physical examination, medical history, laboratory assessment,
baseline electrocardiography test, and chest x-ray. Laboratory
analysis of collected blood samples was done at sites certiﬁed
by the Korean Association of Quality Assurance for Clinical
Laboratories and have regular follow-up of quality-care perform-
ance. Laboratory parameters included complete blood cell
count, blood chemistry (ie, potassium, creatinine, calcium, AST,
ALT, albumin, alkaline phosphatase, total bilirubin, prothrombin
time, HbA1c, glucose, total cholesterol, HDL cholesterol, LDL
cholesterol, triglyceride, high-sensitivity C-reactive protein [hs-
CRP], and chest radiography. Laboratory analysis was veriﬁed
according to prespeciﬁed normal ranges accepted by the institu-
tional review board at the study center and a central coordinating
committee.
At each clinic visit, sitting cuff SBP, DBP, heart rate, body
weight, and height were recorded. To ensure consistency of
through values, these measurements were taken at the same
time of day. For each patient, blood pressure and heart rate were
measured in each arm after patients were seated for at least
5 minutes, using a noninvasive oscillometric automatic blood
pressure monitor (MX3; Omron Healthcare, Hoofddorp, the Neth-
erlands). Three consecutive recordings were taken, each separated
by at least 5 minutes. The mean of the 2 higher blood pressure
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from the analysis if they had a discrepancy of 45 mm Hg
between any 2 mean blood pressure measurements or a
discrepancy of 420 mm Hg between the blood pressure meas-
urements in both arms.
Edema regression time (ERT) was measured at the pretibial
area twice during the study, at baseline (ﬁrst visit) and 14 weeks
after treatment.
The primary efﬁcacy end points were the mean change in
SiSBP from baseline to Week 14 and the mean change in ERT from
baseline to Week 14. The secondary efﬁcacy end points were the
incidence of adverse events in each treatment group and the
mean change in SiDBP from baseline to post-treatment Week 14.
Tolerability
At each study visit, tolerability was assessed by evaluating
medical history and laboratory measurements. Investigators col-
lected information about laboratory measurements and clinical
adverse events (AEs) by asking each patient a standardized
question. All AEs occurring after treatment until the follow-up
visit or the last visit were recorded in case report forms and
reported appropriately. Furthermore, all AEs were evaluated by
the investigator for relationship to the study drug (ie, deﬁnitely
related, probably related, possibly related, probably not related,
deﬁnitely not related, or unknown) and for strength of event (ie,
mild, moderate, or severe). A clinical AE that results in death, is
life-threatening, requires hospitalization or prolongation of exist-
ing hospitalization, results in signiﬁcant permanent disability, or
congenital anomaly was deﬁned as a serious AE. If a laboratory or
clinical AE was considered to be associated with the study drug
and was serious enough to merit possible discontinuation of
treatment, the clinical investigators determined if treatment with
the study drug should be discontinued.
Compliance evaluation
To determine the compliance rate, the investigator counted all
unused medications returned by patients at each visit. Compli-
ance rate was calculated as follows:
Compliance rate (%) ¼ number of drugs actually taken / duration
of prescription  100.
Information about compliance to study treatment was
recorded in the case report forms, including a reason for missed
dose, if applicable. Patients who had compliance rate o70% at
more than 2 visits were withdrawn from the study.Statistical Analysis
This is a noninferiority study. To demonstrate that the efﬁcacy
of lacidipine was not inferior to that of amlodipine, the lower
bound of the 2-sided 90% (1-sided 95%) CI for the difference in
SBP between the 2 groups after 14 weeks of treatment was
calculated, and evaluated in comparison with the prespeciﬁed
noninferiority margin of -5 mm Hg. If the lower bound of the
1-sided 95% CI is above -5 mm Hg, lacidipine would be assumed
to be noninferior to amlodipine. The analyses of all other efﬁcacy
end points were performed at 2-sided signiﬁcance level o5%.
The efﬁcacy analysis population for this study was the intent-
to-treat (ITT) population and per-protocol (PP) population. The
ITT population consisted of all randomized patients. Of the ITT
population, those who did not complete the 14 weeks of treat-
ment had a compliance rate of o70% for 2 times or more, or had
used a prohibited medication during the study were excluded
from the PP population.The efﬁcacy analyses were performed on both ITT and PP
populations; and the primary efﬁcacy analysis was performed
using the PP population analysis. For imputation of missing data
for Week 14 SiSBP, ERT, or SiDBP, the last-observation-carried-
forward method was used. The safety analysis was performed on
the ITT population.
Baseline characteristics were compared between the 2 treat-
ment groups. Continuous variables were analyzed using the
Student t test, and categorical variables were analyzed and
compared between 2 groups using w2 test or Fisher’s exact test.
Whether or not treatment effect was affected by baseline char-
acteristics was analyzed using analysis of covariance. Incidences
of AEs were analyzed and compared between the 2 groups, using
w2 test or Fisher’s exact test. Differences were considered statisti-
cally signiﬁcant if P r 0.05.Results
Baseline characteristics
A total of 322 patients were enrolled in this study, and 317 of
them provided written consent.
Excluding 2 patients who failed the screening, 315 patients were
included in the ITT population (154 men, mean age 67.6 years,
mean body weight 62.6 kg) and were randomly assigned to receive
lacidipine (n ¼ 162) or amlodipine besylate (n ¼ 153) (Figure 1).
There was no signiﬁcant difference in mean (SD) age between
the lacidipine group (68.1 [6.1] years [range 56–83 years] and
amlodipine group (67.1 [5.7] years [range 56–82 years]). There was
also no signiﬁcant difference between the 2 groups in sex (lacidi-
pine 79 men [49%], amlodipine 75 men [49%]). Baseline SiSBP and
SiDBP were comparable between the treatment groups, with 152.1
(10.3) mm Hg and 90.6 (8.9) mm Hg in the lacidipine group and
151.9 (10.9) mm Hg and 90.7 (9.5) mm Hg in the amlodipine group,
respectively (Table I). With regard to baseline physical examination
and medical history such as history of antihypertensive treatment,
there was no signiﬁcant difference between the 2 groups.
Furthermore, there were no patients showing clinically signiﬁcant
abnormalities in 12-lead electrocardiography and chest x-ray.
With regard to clinical laboratory values, there was no signiﬁcant
difference between the 2 groups in hemoglobin, electrolyte, AST,
ALT, total bilirubin, prothrombin time, or HbA1C.
There was no signiﬁcant difference in the dropout rate
between the 2 groups. Of 315 patients randomized, 29 (9.2%)
were early discontinued from the study: 12 patients from the
lacidipine group and 17 patients from the amlodipine group.
There were 3 patients (1.9%) (1 patient with each of skin rash,
severe headache, and facial ﬂushing) in the lacidipine group and
3 patients (1 patient with each of facial ﬂushing, drowsiness, and
severe fatigue) in the amlodipine group, who discontinued the
study due to AEs. A total of 6 patients (1.9%) were discontinued
due to noncompliance, and 11 patients (3.5%) were discontinued
due to consent withdrawal. Thus PP population who completed
the study according to the protocol contained 286 patients
(n ¼ 150 for lacidipine, n ¼ 136 for amlodipine) (Figure 1).Effectiveness
In older Korean patients with mild-to-moderate hypertension,
both PP and ITT analyses were performed to assess the primary
end point and to compare the therapeutic effect of lacidipine and
amlodipine.
The difference in change in mean SiSBP between the lacidipine
and amlodipine groups was 1.7 mm Hg (95% CI -3.4 to 1.3).
Figure 1. Flow diagram of study patients. AE, adverse event.
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the lower limit of -5 mm Hg, lacidipine was considered non-
inferior to amlodipine (Table II).
In the PP analysis, mean SiSBP decreased signiﬁcantly from
baseline after 14 weeks of treatment in the 2 groups (lacidipine from
151.6 [10.2] mm Hg to 132.7 [11.1] mm Hg, amlodipine from 151.7
[11.2] mm Hg to 131.1 [11.2] mm Hg; both P o 0.001) (Figure 2).
The difference between the 2 groups in mean change in SiSBP from
baseline to Week 14 was not signiﬁcant (lacidipine -18.9 [12.7] mm
Hg, amlodipine, -20.6 [12.4] mm Hg; P ¼ 0.25) (Table II).
Mean SiDBP decreased signiﬁcantly after 14 weeks of treatment in
the 2 groups (lacidipine from 90.3 [9.0] mm Hg to 81.6 [7.4] mm Hg,
amlodipine from 90.4 [9.7] mm Hg to 81.7 [7.1] mm Hg; both
P o 0.001) (Figure 2). The difference between the 2 groups in
mean (SD) change in SiDBP from baseline to Week 14 was not
signiﬁcant (lacidipine -8.7 [8.3] mm Hg, amlodipine, -8.7 [8.6]
mm Hg; P ¼ 0.95) (Table II).
In the ITT analysis, mean (SD) SiSBP decreased signiﬁcantly
from baseline after 14 Weeks of treatment in the 2 groups
(lacidipine from 152.1 [10.3] mm Hg to 133.2 [11.3] mm Hg,
amlodipine from 151.9 [10.9] mm Hg to 131.5 [11.3] mm Hg;
both P o 0.001) (Figure 3). The difference between the 2 groups
in mean (SD) change in SiSBP from baseline to Week 14 was not
signiﬁcant (lacidipine -18.4 [12.7] mm Hg, amlodipine -19.4
[12.7] mm Hg; P ¼ 0.47) (Table II).
Mean (SD) SiDBP decreased signiﬁcantly after 14 weeks of
treatment in the 2 groups (lacidipine from 90.6 [8.9] mm Hg to
81.8 [7.4] mm Hg, amlodipine, from 90.7 [9.5] mm Hg to 81.9
[7.2] mm Hg; both P o 0.001) (Figure 3). The difference between
the 2 groups in mean (SD) change in SiDBP from baseline to Week14 was not signiﬁcant (lacidipine -8.6 [8.3] mm Hg, amlodipine -
8.3 [8.5] mm Hg; P ¼ 0.74) (Table II).
The difference between the 2 groups in SiSBP response rate did
not reach statistical signiﬁcance, with 73.5% of patients (119 out
of 162) in the lacidipine group and 78.4% (120 out of 153) of those
in the amlodipine group achieving this end point. The difference
between the 2 groups in SiDBP response rate also was not
signiﬁcant, with 81.5% of patients (132 out of 162) in the
lacidipine group and 83.7% of patients (128 out of 153) in the
amlodipine group achieving this end point (Table III).
The result of SiSBP and SiDBP changes in the both ITT analysis
and PP analysis had similar patterns in both groups (all P o 0.001
vs baseline) (Figures 2 and 3).
The changes in ERT from baseline to Week 14 are presented in
the Figure 4. ERT measured at baseline and at the end of Week 14
showed no statistically signiﬁcant difference between the lacidi-
pine group and amlodipine group at both time points (all
P 4 0.05).Subgroup Analysis of patients with ISH
The number of patients who had ISH (SiSBP Z 140 mm Hg and
SiDBP o90 mm Hg) was 60 in the lacidipine group and 58 in the
amlodipine group (PP analysis). No signiﬁcant difference between
the 2 groups was observed in baseline clinical and laboratory
characteristics. There was no signiﬁcant difference between the
2 groups in mean (SD) age (lacidipine, 69.1 [6.3] years, amlodi-
pine, 68.1 [5.21] years; P ¼ 0.36), SiSBP (lacidipine 148.8 [8.0]
mm Hg, amlodipine 147.3 [6.9] mm Hg; P ¼ 0.26), SiDBP
Table I
Baseline characteristics of study patients.
Characteristic Lacidipine
(n ¼ 162)
Amlodipine
(n ¼ 153) P
Age, y 0.16
Mean (SD) 68.1 (6.1) 67.1 (5.7)
Range 56–83 56–82
Sex, n (%) 0.96
Men 79 (48.8) 75 (49.0)
Women 83 (51.2) 78 (51.0)
Height, cm 0.74
Mean (SD) 159.5 (9.1) 159.9 (9.3)
Range 137–184 140–188
Weight, cm 0.70
Mean (SD) 62.3 (8.9) 62.7 (10.9)
Range 42–91 37–100
Smoking, n (%) 0.08
Current smoker 13 (8.0) 22 (14.4)
Exsmoker 44 (27.2) 29 (19.0)
Nonsmoker 105 (64.8) 102 (66.7)
Alcohol use, n (%) 0.74
Yes 58 (35.8) 52 (34.0)
No 104 (64.2) 101 (66.0)
Blood pressure, mm Hg
Sitting systolic 0.85
Mean (SD) 152.1 (10.3) 151.9 (10.9)
Range 131–180 131–180
Sitting diastolic 0.90
Mean (SD) 90.6 (8.9) 90.7 (9.5)
Range 62–120 54–109
Heart rate, bpm 0.35
Mean (SD) 72.2 (9.5) 71.2 (9.1)
Range 52–98 50–102
Glycosylated hemoglobin, % 0.68
Mean (SD) 5.9 (0.8) 5.9 (0.7)
Range 3.5–8.0 4.2–8.0
Table II
Blood pressure parameters at baseline and end of treatment (Week 14) with
lacidipine or amlodipine in an elderly Korean population.
Parameter Lacidipine Amlodipine P
’————————Mean (SD)————————-
Per-protocol anaylsis
n 150 136
SiSBP, mm Hg
Baseline 151.6 (10.2) 151.7 (11.2) 0.94
Week 14 132.7 (11.1)* 131.1 (11.2)* 0.22
Change 18.9 (12.7) 20.6 (12.4) 0.25
SiDBP, mm Hg
Baseline 90.3 (9.0) 90.4 (9.7) 0.96
Week 14 81.6 (7.4)* 81.7 (7.1)* 0.89
Change 8.7 (8.3) 8.7 (8.6) 0.95
Intent-to-treat analysis
n 162 153
SiSBP, mm Hg
Baseline 152.1 (10.3) 151.9 (10.9) 0.85
Week 14 133.2 (11.3)* 131.5 (11.3)* 0.19
Change 18.4 (12.7) 19.4 (12.7) 0.47
SiDBP, mm Hg
Baseline 90.6 (8.9) 90.7 (9.5) 0.90
Week 14 81.8 (7.4)* 81.9 (7.2)* 0.88
Change 8.6 (8.3) 8.3 (8.5) 0.74
SiDBP, sitting diastolic blood pressure; SiSBP, sitting systolic blood pressure.
n P o 0.001 versus baseline.
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0.67), ERT (lacidipine 198.4 [216.7] seconds, amlodipine 224.1
[240.2] seconds; P ¼ 0.75), and hs-CRP (lacidipine 2.52 [4.47] mg/L,
amlodipine 1.10 [1.47] mg/L; P ¼ 0.33).
There was no signiﬁcant difference between the 2 groups in
the blood pressure-lowering effect from baseline to Week 14
(Figure 5). There was no signiﬁcant difference between the
2 groups in mean (SD) change in SiSBP (lacidipine -18.1 [11.9]
mm Hg; amlodipine -19.7 [12.3] mm Hg; P ¼ 0.62), SiDBP
(lacidipine -3.5 [7.0] mm Hg; amlodipine -2.7 [7.7] mm Hg; P ¼
0.52), and ERT (lacidipine -23.4 [63.8] seconds; amlodipine -34.5
[112.2] seconds; P ¼ 0.52).Tolerability
There was no signiﬁcant difference between the 2 groups in
the rate of clinical and laboratory AEs (Table IV). The rate of
overall AEs was 7.4% (12 patients in 162 patients) in the lacidipine
group and 11.1% (17 patients in 153 patients) in the amlodipine
group (P 4 0.05).
The most common drug-related AEs were headache (n ¼ 3),
facial ﬂushing (n ¼ 2), and dizziness (n ¼ 2) in the lacidipine
group, and headache (n ¼ 6), facial ﬂushing (n ¼ 5) in the
amlodipine group. In addition, 1 patient in the lacidipine group
and 5 patients in the amlodipine group reported low extremity
edema. Cardiovascular system, general, and skin AEs were com-
parable between the 2 groups, and no signiﬁcant difference
between the 2 groups in the rate of other AEs was observed.
Laboratory analysis, including blood cell count and blood
chemistry, showed no abnormal ﬁnding in either group, as
veriﬁed by prespeciﬁed normal ranges accepted by theinstitutional review board at each study center and the central
coordinating committee. The number of patients who required
treatment discontinuation due to drug-related clinical AEs deter-
mined by investigators was 3 in the lacidipine group (1 patient
with each of skin rash, severe headache, and facial ﬂushing) and
3 in the amlodipine group (1 patient with each of facial ﬂushing,
drowsiness, and severe fatigue).Discussion
According to a MEDLINE search using the terms lacidipine and
amlodipine besylate, this was the ﬁrst prospective, randomized,
head-to-head comparison of lacidipine and amlodipine in the
older patients with hypertension. In patients with hypertension
aged 55 years or older, the effectiveness and AEs of 2 CCBs,
lacidipine and amlodipine, were compared. Overall, in this 14-
week, multicenter, prospective, randomized, open-label, nonin-
feriority clinical trial, lacidipine was found to be noninferior to
amlodipine besylate in the reduction of SiSBP and SiDBP, SiSBP
reduction rate, clinical and laboratory AE rate, and overall toler-
ability proﬁles in older Korean population with mild-to-moderate
hypertension both in the PP and ITT analysis.
SBP is an independent risk factor for stroke, coronary artery
disease, heart failure, and renal failure.9 SBP tends to increase
linearly with age, whereas DBP increases in parallel with SBP until
age of 55 years, and then tends to decrease after age of 55 years
due to increased central arterial stiffness.1 Therefore, the preva-
lence of ISH increases with age, and ISH is considered an
important cardiovascular or cerebrovascular risk factor. In addi-
tion, the hemodynamic pattern is different between young and
older patients with hypertension. Most young patients with
hypertension tend to maintain the hyperkinetic state, with
increased heart rate and consequently increased cardiac index
and an increase in left ventricular ejection fraction. In contrast,
older patients with hypertension tend to have decreased systolic
function and subsequently depressed cardiac reserve, which
results in impaired diastolic function at rest and markedly
decreased diastolic function during exercise, compared with
Figure 2. Sitting (A) systolic blood pressure (SiSB) and (B) diastolic blood pressure
(SiDBP) changes during 14-week treatment with lacidipine or amlodipine in older
Korean patients with mild-to-moderate hypertension (per-protocol population).
*Po 0.001 versus baseline. No signiﬁcant differences were found between the
2 groups.
Figure 3. Sitting (A) systolic blood pressure (SiSBP) and (B) diastolic blood
pressure (SiDBP) changes during 14-week treatment with lacidipine or amlodipine
in older Korean patients with mild-to-moderate hypertension (intent-to-treat-
ment population). *P o 0.001 versus baseline. No signiﬁcant differences were
found between the 2 groups.
Table III
Response rates with 14-week treatment with lacidipine or amlodipine in elderly
Korean patients (intent-to-treat population).*
Parameter
Lacidipine
(n ¼ 162)
Amlodipine
(n ¼ 153)
SiSBPy 119 (73.5) 120 (78.4)
SiDBPz 132 (81.5) 128 (83.7)
SiDBP, sitting diastolic blood pressure; SiSBP, sitting systolic blood pressure.
n Values are presented as n (%). No signiﬁcant between-group differences
were found.
y Response deﬁned as o140 mm Hg at Week 14.
z Response deﬁned as o90 mm Hg at Week 14 or an absolute reduction of
410 mm Hg.
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attain adequate blood pressure control in older patients. With
adequate control of blood pressure, cardiovascular morbidity and
mortality can be signiﬁcantly reduced in elderly patients with
hypertension.4,5,10,11
Antihypertensive medications that are effective in elderly
persons include CCBs and diuretics. Amlodipine is widely used
for the treatment of hypertension and angina pectoris and has a
relatively fast onset of activity. The effectiveness of amlodipine
has been demonstrated in many studies. The Valsartan Antihy-
pertensive Long-Term Use Evaluation study12 conducted in
15,245 patients with hypertension showed that patients treated
with amlodipine 5 to 10 mg/d had a more signiﬁcant reduction in
SBP and DBP than those treated with valsartan 150 to 300 mg/d
(Po 0.001).12 In the Comparison of Amlodipine vs Enalapril to
Limit Occurrences of Thrombosis trial,13 patients with coronary
artery disease and normal blood pressure who were treated with
amlodipine 10 mg/d over 2 years had signiﬁcantly lower rates of
cardiovascular events than those in the placebo group (P ¼ 0.03);
however, the study failed to demonstrate that the use of amlodi-
pine might prevent progression of atherosclerosis, compared with
placebo.
In contrast, lacidipine, a third-generation lipophilic dihydro-
pyridine CCB, has intrinsically slow onset of activity, which
results in less reﬂex tachycardia14 and long duration of action
and high degree of vascular selectivity. The results of this study
demonstrated that therapeutic effectiveness of lacidipine in
reducing SBP and DBP was comparable to that of amlodipine,
and we believe these ﬁndings imply comparable cardiovascular
event rate reduction. Findings in the European Lacidipine Study
on Atherosclerosis,15 in which 2334 patients aged 45 to 75 yearswho had mild-to-moderate essential hypertension were followed,
showed that the lacidipine group had signiﬁcantly lower athero-
sclerotic progression and plaque formation in the carotid artery
than the atenolol group. Because the extent of blood pressure
reduction of Korean patients in this study was comparable to that
of European patients, long-term follow-up for cerebrovascular
event was deemed necessary; however, this study could not
provide data on cardiovascular event rate due to the limited
length of follow-up. Thus, in an Asian country where the preva-
lence of cerebrovascular events is relatively high, further evalua-
tion is clearly warranted.
According to the subgroup analysis in patients with ISH, the
reduction in SBP in the subgroup was consistent with that in the
total population, but the reduction in DBP in the subgroup was
relatively lower. Thus, it was concluded that in patients with ISH
who have normal DBP, lacidipine is as effective and safe as
amlodipine.
Table IV
Adverse events (AEs) during 14-week treatment with lacidipine or amlodipine in
elderly Korean patients with uncomplicated, mild-to-moderate, essential hyper-
tension (intent-to-treat population).*
AE
Lacidipine
(n ¼ 162)
Amlodipine
(n ¼ 153)
Nervous system
Headache 3 (1.9) 6 (3.9)
Dizziness 2 (1.2) 1 (0.7)
Drowsiness 0 1 (0.7)
Hoarseness 0 0
Tremor 0 0
Cardiovascular system
Chest discomfort 0 0
Dyspnea 1 (0.6) 0
Palpitation 1 (0.6) 1 (0.7)
Syncope 0 0
General
Fatigue 0 1 (0.7)
Facial ﬂushing 2 (1.2) 5 (3.3)
Edema, low
extremity
1 (0.6) 5 (3.3)
Dry mouth 0 0
Skin
Rash 1 (0.6) 0
Laboratory
AST/ALT elevation 0 1 (0.7)
Dyslipidemia 1 (0.6) 2 (1.3)
Anemia 0 0
Total patients
With at least 1 AE 12 (7.4) 17 (11.1)
With no AEs 150 (92.6) 136 (88.9)
Withdrawn due to
AEs
3 (1.9) 3 (2.0)
ALT, alanine aminotrasferase; AST, aspartate aminotransferase.
Figure 4. Comparison of edema regression time between lacidipine and amlodi-
pine groups at baseline and 14 weeks after treatment. No signiﬁcant between-
group differences were found.
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group and amlodipine group in ERT, indicating that the rate of
edema, a most common AE associated with CCBs, in the lacidipine
group was comparable to that in the amlodipine group.
The rates of AEs, including those of the autonomic nervous
system and cardiovascular system, dermatologic, and laboratory,
were not signiﬁcantly different between the 2 groups. In previous
studies,16 the rate of edema related to the use of CCBs was
reported up to 34%; however, the occurrence rate of low extrem-
ity edema (lacidipine 0.6%, amlodipine 3.3%) and facial ﬂushing
(lacidipine 1.2%, amlodipine 3.3%) was very low in this study, and
there was no signiﬁcant difference between the 2 groups in ERT.
Three patients from each of the 2 groups were discontinued fromFigure 5. Subgroup analysis of sitting (A) systolic blood pressure (SiSBP) and
(B) diastolic blood pressure (SiDBP) changes during 14-week treatment with
lacidipine or amlodipine in older Korean patients with isolated systolic hyperten-
sion (per-protocol population). *P o 0.001 versus baseline. No signiﬁcant
differences were found between two groups.
n Values are presented as n (%). Some patients experienced 41 AE. No signiﬁcant
between-group differences were found.the study due to AEs, but none experienced a serious AE that
required hospitalization or was life-threatening. Furthermore, the
drug compliance rate was comparable between the 2 groups.
There was no signiﬁcant difference in the rate of early discontin-
uation from the study between the 2 groups.
Limitations of this study include a relatively small sample size,
short duration of follow-up, and use of clinical blood pressure
instead of 24-hour blood pressure monitoring.Conclusions
In this prospective study, we found that lacidipine was non-
inferior to amlodipine besylate in the reduction of blood pressure
in older Korean patients with uncomplicated, mild-to-moderate
essential hypertension or ISH. The safety and tolerability of
lacidipine were consistent with those of amlodipine besylate.Acknowledgments
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